<DOC>
	<DOC>NCT01454050</DOC>
	<brief_summary>The objective of this study is to prove the safety and efficacy of the Lumax 740 ICD family. Primarily, the newly implemented RV/LV Capture Control algorithm is evaluated, which automatically measures the RV/LV threshold and subsequently adjusts the pacing output.</brief_summary>
	<brief_title>Lumax 740 Master Study</brief_title>
	<detailed_description />
	<criteria>Standard indication for single, dual, or triple chamber ICD. Legal capacity and ability to consent Signed patient informed consent In addition for HFT devices: Bipolar LVlead with a min. distance of 15 mm between tip and ring True bipolar RV lead Standard contraindication for single, dual, or triple chamber ICD. Age &lt; 18 years Pregnant or breastfeeding woman Cardiac surgery planned within the next 6 months Life expectancy of less than 6 months Participating in any other clinical study of an investigational cardiac drug or device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ICD therapy</keyword>
	<keyword>RV/LV Capture Control</keyword>
	<keyword>Safety and Efficacy</keyword>
</DOC>